Search from website

Antibody discovery

Leave your inquiry here:

Contact Luka

Name(Required)

Antibody discovery

Icosagen has implemented a toolbox of diverse antibody discovery technology platforms to yield specific high affinity antibodies for any target class. To extract highly selective binders against small molecules, membrane proteins (using pseudotyped VLPs), and recombinant proteins, we combine in vivo and in vitro methods, from B-cell cloning to fully synthetic phage libraries.

Based on state-of-the-art high-throughput analytical capabilities, these antibodies can then be further optimized, formatted into any desired frameworks and seamlessly produced from milligrams to kilograms.

Let's discuss antibody discovery!

Antibody discovery by phage display

Our phage display antibody discovery service, which utilizes synthetic libraries customized for various targets, is a powerful high-throughput and cost-effective in vitro platform for the rapid identification and characterization of high-quality antibodies.

Phage display in combination with in vivo-immunization and our in-house B-cell cloning platform HybriFree®, generates diverse sets of highly specific, functional and non-overlapping epitope antibodies.

Why choose phage display for antibody discovery?

RAPID &
REPEATED
SCREENING

RAPID & REPEATED SCREENING

Phage display allows for rapid screening of enormous numbers of ligands against the target, combined with individually adjusted, iterative selection conditions.

ADAPTABLE &
FLEXIBLE

ADAPTABLE & FLEXIBLE

The phage display team has a deep expertise in individually chosen selection techniques, including normal (direct, indirect, in-solution), competitive (with peptides, VLPs, recombinant proteins) and masked (competitive, selective, free) selections.

DIVERSE
LIBRARIES

DIVERSE LIBRARIES

We created a range of different libraries, including synthetic and hyperimmune options, as well as libraries tailored to specific objectives, such as thermostability, humanization and affinity maturation.

HIGH
DIVERSITY

HIGH DIVERSITY

Phage display allows for the generation of libraries of billions of antibody fragments, providing a high degree of diversity that support the identification of rare or unique antibodies.

BACKED
WITH
ANALYTICAL
CAPABILITIES

BACKED WITH ANALYTICAL CAPABILITIES

All this, combined with cutting-edge internal analytical, engineering, and antibody production capabilties robustly unvails sets of specific binders against just about any structure.

Phage display workflow

Antibody discovery with B-cell panning via HybriFree technology

Our proprietary HybriFree technology is based on B-cell cloning, and is used for efficient discovery of monoclonal antibodies and their immediate production in mammalian cells. HybriFree makes antibody discovery rapid and flexible, and allows cloning antibodies even from recovered patients’ PBMCs and existing hybridomas.

All antibodies discovered through HybriFree platform can readily be produced transiently at mg to gram range or developed into stable high producer CHO cell lines.

Why choose HybriFree for antibody discovery?

SEAMLESS
TRANSITION

SEAMLESS TRANSITION

From discovery to large scale production.

FAST in vivo
APPROACH

FAST in vivo APPROACH

After immunization stage, biologically active antibodies with optimal physicochemical properties can be delivered as fast as 8 to 9 weeks.

IMMUNIZATION
AGILITY

IMMUNIZATION AGILITY

Immunization of chickens with DNA, peptides, proteins or VLPs can be used to develop antibodies against hard-to-express proteins.

FLEXIBLE

FLEXIBLE

All identified sequences can be used for production of different immune molecules (bi-specifics, chimeras, antibody fragmens etc.)

COMPLEX
TARGETS

WORKS WITH COMPLEX TARGETS

Integral membrane proteins as feasible targets.

HybriFree workflow

REMEMBER: ANTIGEN MATTERS! Even the smallest difference between an antigen and the natural target protein will affect the antibody specificity and biological function.

Icosagen-discovered antibodies can be used for IVD purposes or developed as biopharmaceutical drug candidates. 

Hybridoma sequencing platform — HybriRescue

We clone antibodies from hybridomas, provided by our customers, and produce them at requested scales.

In addition, we deliver the cDNA sequence encoding the antibody variable heavy (VH) and light (VL) domains.

ANTIBODY
ENGINEERING

ANTIBODY ENGINEERING

Essential for monoclonal antibody engineering, humanization, function optimization or patent applications.

DELIVERS
SEQUENCE

DELIVERS ANTIBODY SEQUENCE

With determined antibody sequence there is always opportunity to reproduce it, which eliminates the risk of excellent antibodies being permanently lost due to loss of cell culture.

PATENT
APPLICATION

PATENT APPLICATION

Patent the sequences of your unique variable domains that provides opportunities for investing in R&D.

HybriRescue workflow

Customized immunization

We have implemented different immunization technology platforms, which are specifically designed to tackle diverse antigen classes. While immunizations with soluble recombinant proteins are often highly effective, more complex targets, such as multi-pass transmembrane proteins, present a serious challenge, as they are difficult to purify in native 3D-structure. 
To overcome this, we engineered a proprietary display & discovery platform, that combines multi-pass transmembrane protein pseudotyped VLPs with nucleic acid immunization.

With this, and over 15 years of experience in DNA immunizations,we simply know how to create specific and functional affinity ligands with chickens and rabbits.

Why develop antibodies in chickens?

GREATER
EVOLUTIONARY
DISTANCE

GREATER EVOLUTIONARY DISTANCE

The evolutionary distance between chickens and humans is much greater than between humans and mammals, making chickens a more immunogenic host species for conserved targets. Hence, increasing the likelihood to raise specific antibodies in antibody discovery.

LARGER & MORE
HYDROPHILIC
CDRs

LARGER & MORE HYDROPHILIC CDRs

The structure and sequence of variable regions differ in length and amino acid composition from those of human antibodies. These increased properties enable them to bind to a broader range of antigens, including notoriously difficult-to-target molecules, such as GPCRs and transporters, or other integral membrane proteins.

PICOMOLAR
AFFINITIES

PICOMOLAR AFFINITIES WITHOUT AFFINITY MATURATION

Chicken-generated antibodies typically have high affinities, without the need for further affinity maturation, simplifying and speeding up the discovery process.
Antibody
development
Protein
production
Cell line
development
Analytics

Ask for your custom solution

Shopping Cart